vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and GCM Grosvenor Inc. (GCMG). Click either name above to swap in a different company.
GCM Grosvenor Inc. is the larger business by last-quarter revenue ($177.1M vs $139.2M, roughly 1.3× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 32.8%, a 2.6% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 7.2%). GCM Grosvenor Inc. produced more free cash flow last quarter ($175.0M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 27.5%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
GCM Grosvenor is an American alternative asset management firm, with approximately $76 billion in assets under management and approximately 530 professionals as of 2023.
ADMA vs GCMG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $177.1M |
| Net Profit | $49.4M | $58.2M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 30.9% |
| Net Margin | 35.5% | 32.8% |
| Revenue YoY | 18.4% | 7.2% |
| Net Profit YoY | -55.9% | 149.2% |
| EPS (diluted) | $0.20 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $177.1M | ||
| Q3 25 | $134.2M | $135.0M | ||
| Q2 25 | $122.0M | $119.7M | ||
| Q1 25 | $114.8M | $125.8M | ||
| Q4 24 | $117.5M | $165.3M | ||
| Q3 24 | $119.8M | $122.9M | ||
| Q2 24 | $107.2M | $117.0M | ||
| Q1 24 | $81.9M | $108.9M |
| Q4 25 | $49.4M | $58.2M | ||
| Q3 25 | $36.4M | $10.5M | ||
| Q2 25 | $34.2M | $15.4M | ||
| Q1 25 | $26.9M | $463.0K | ||
| Q4 24 | $111.9M | $7.6M | ||
| Q3 24 | $35.9M | $4.2M | ||
| Q2 24 | $32.1M | $4.8M | ||
| Q1 24 | $17.8M | $2.1M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 30.9% | ||
| Q3 25 | 38.0% | 32.7% | ||
| Q2 25 | 35.1% | 16.1% | ||
| Q1 25 | 30.4% | 12.2% | ||
| Q4 24 | 32.6% | 26.4% | ||
| Q3 24 | 33.1% | 20.3% | ||
| Q2 24 | 36.6% | 17.8% | ||
| Q1 24 | 26.7% | -14.7% |
| Q4 25 | 35.5% | 32.8% | ||
| Q3 25 | 27.1% | 7.8% | ||
| Q2 25 | 28.1% | 12.9% | ||
| Q1 25 | 23.4% | 0.4% | ||
| Q4 24 | 95.2% | 4.6% | ||
| Q3 24 | 30.0% | 3.4% | ||
| Q2 24 | 29.9% | 4.1% | ||
| Q1 24 | 21.7% | 2.0% |
| Q4 25 | $0.20 | $0.23 | ||
| Q3 25 | $0.15 | $0.16 | ||
| Q2 25 | $0.14 | $0.05 | ||
| Q1 25 | $0.11 | $-0.02 | ||
| Q4 24 | $0.45 | $0.09 | ||
| Q3 24 | $0.15 | $0.03 | ||
| Q2 24 | $0.13 | $0.04 | ||
| Q1 24 | $0.08 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $242.1M |
| Total DebtLower is stronger | $72.1M | $428.4M |
| Stockholders' EquityBook value | $477.3M | $27.0M |
| Total Assets | $624.2M | $813.8M |
| Debt / EquityLower = less leverage | 0.15× | 15.87× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $242.1M | ||
| Q3 25 | $61.4M | $182.7M | ||
| Q2 25 | $90.3M | $136.3M | ||
| Q1 25 | $71.6M | $94.5M | ||
| Q4 24 | $103.1M | $89.5M | ||
| Q3 24 | $86.7M | $98.4M | ||
| Q2 24 | $88.2M | $73.9M | ||
| Q1 24 | $45.3M | $41.9M |
| Q4 25 | $72.1M | $428.4M | ||
| Q3 25 | $72.4M | $429.3M | ||
| Q2 25 | — | $430.2M | ||
| Q1 25 | — | $431.1M | ||
| Q4 24 | $72.3M | $432.0M | ||
| Q3 24 | — | $432.9M | ||
| Q2 24 | — | $433.8M | ||
| Q1 24 | — | $384.0M |
| Q4 25 | $477.3M | $27.0M | ||
| Q3 25 | $431.2M | $-7.4M | ||
| Q2 25 | $398.3M | $-12.3M | ||
| Q1 25 | $373.4M | $-28.3M | ||
| Q4 24 | $349.0M | $-27.6M | ||
| Q3 24 | $231.9M | $-31.9M | ||
| Q2 24 | $188.3M | $-28.5M | ||
| Q1 24 | $153.7M | $-26.4M |
| Q4 25 | $624.2M | $813.8M | ||
| Q3 25 | $568.7M | $685.9M | ||
| Q2 25 | $558.4M | $636.9M | ||
| Q1 25 | $510.6M | $579.8M | ||
| Q4 24 | $488.7M | $612.7M | ||
| Q3 24 | $390.6M | $575.0M | ||
| Q2 24 | $376.4M | $543.9M | ||
| Q1 24 | $350.9M | $497.3M |
| Q4 25 | 0.15× | 15.87× | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $183.5M |
| Free Cash FlowOCF − Capex | $34.6M | $175.0M |
| FCF MarginFCF / Revenue | 24.8% | 98.8% |
| Capex IntensityCapex / Revenue | 0.8% | 4.8% |
| Cash ConversionOCF / Net Profit | 0.72× | 3.16× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $326.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $183.5M | ||
| Q3 25 | $13.3M | $79.8M | ||
| Q2 25 | $21.1M | $42.0M | ||
| Q1 25 | $-19.7M | $33.3M | ||
| Q4 24 | $50.2M | $148.8M | ||
| Q3 24 | $25.0M | $69.0M | ||
| Q2 24 | $45.6M | $17.5M | ||
| Q1 24 | $-2.2M | $24.2M |
| Q4 25 | $34.6M | $175.0M | ||
| Q3 25 | $-1.1M | $78.3M | ||
| Q2 25 | $18.7M | $40.8M | ||
| Q1 25 | $-24.4M | $32.1M | ||
| Q4 24 | $47.5M | $132.0M | ||
| Q3 24 | $24.0M | $62.2M | ||
| Q2 24 | $43.6M | $12.8M | ||
| Q1 24 | $-4.6M | $20.0M |
| Q4 25 | 24.8% | 98.8% | ||
| Q3 25 | -0.8% | 58.0% | ||
| Q2 25 | 15.3% | 34.1% | ||
| Q1 25 | -21.2% | 25.5% | ||
| Q4 24 | 40.4% | 79.9% | ||
| Q3 24 | 20.0% | 50.6% | ||
| Q2 24 | 40.7% | 10.9% | ||
| Q1 24 | -5.6% | 18.4% |
| Q4 25 | 0.8% | 4.8% | ||
| Q3 25 | 10.7% | 1.1% | ||
| Q2 25 | 2.0% | 1.0% | ||
| Q1 25 | 4.1% | 0.9% | ||
| Q4 24 | 2.3% | 10.1% | ||
| Q3 24 | 0.9% | 5.5% | ||
| Q2 24 | 1.9% | 4.0% | ||
| Q1 24 | 2.9% | 3.9% |
| Q4 25 | 0.72× | 3.16× | ||
| Q3 25 | 0.36× | 7.61× | ||
| Q2 25 | 0.62× | 2.72× | ||
| Q1 25 | -0.73× | 71.84× | ||
| Q4 24 | 0.45× | 19.54× | ||
| Q3 24 | 0.70× | 16.60× | ||
| Q2 24 | 1.42× | 3.64× | ||
| Q1 24 | -0.12× | 11.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
GCMG
| Asset Management1 | $108.6M | 61% |
| Management Service Incentive Performance Fees | $61.7M | 35% |
| Management Service Incentive Carried Interest | $5.1M | 3% |
| Service Other | $1.8M | 1% |
